Beasley Allen lawyer Navan Ward, Jr., has been appointed to the Plaintiffs Executive Committee (PEC) for the multidistrict litigation (MDL) involving proton pump inhibitor (PPI) drugs linked to kidney damage. Ward is one of five attorneys appointed to the PEC. The U.S. Judicial Panel on Multidistrict Litigation (JPML) granted the plaintiffs’ motion to consolidate PPI in the U.S. District Court in the District of New Jersey under Judge Claire C. Cecchi.
“I’m honored to be selected to work with this incredibly talented group of attorneys to lead this nationwide litigation,” says Ward, who in January helped open and began working from the firm’s new Atlanta office. “The evidence of these products’ defect is very apparent in the early stages of this litigation, so I look forward to continuing our efforts to provide a successful resolution to these claims for all of our clients.”
Plaintiffs are suing PPI manufacturers after developing kidney damage linked to the use of PPIs. Plaintiffs claim the companies should be held accountable for their failure to warn consumers about the drugs’ potential to cause kidney damage. Studies dating back to the 1990s have linked PPIs to kidney problems, including Acute Interstitial Nephritis (AIN), which is inflammation in the spaces between the kidney tubules. PPI use has also been linked to an increased risk of Acute Kidney Injury (AKI or Acute Renal Failure) and Chronic Kidney Disease.
The litigation centers on suits against the manufacturers of a variety of products including four prescription products Prilosec, Nexium, Protonix, and Dexilant; and three over-the-counter products: Prilosec OTC, Prevacid 24-Hour, and Nexium 24 Hour. Pharmaceutical companies included as defendants in the MDL include: Takeda Pharmaceutical Co., AstraZeneca; Pfizer Inc., (and its subsidiaries Wyeth Pharmaceuticals, Inc., Wyeth, LLC, and Wyeth-Ayerst Laboratories); Procter & Gamble Company; and Novartis Consumer Health, Inc. (and its subsidiaries Novartis Vaccines and Diagnostics, Inc. and Novartis Institute for Biomedical Research, Inc).
The litigation is In Re: Proton-Pump Inhibitor Products Liability Litigation, MDL No. 2789.
* * *
Lawyers in our firm’s Mass Torts Section are currently investigating cases involving PPI use and AIN, AKI or Acute Renal Failure, and Chronic Kidney Disease. If you would like more information, contact Navan Ward or Tiffany Birley at 800-898-2034 or by email at Navan.Ward@beasleyallen.com or Tiffany.Birley@beasleyallen.com.